BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Slamon Dennis | Director | Mar 18 '24 | Option Exercise | 79.70 | 10,000 | 797,000 | 40,809 | Mar 20 05:13 PM | BIENAIME JEAN JACQUES | Director | Mar 06 '24 | Sale | 86.71 | 1,000 | 86,713 | 560,203 | Mar 07 05:35 PM | FUCHS HENRY J | President, Worldwide R&D | Mar 05 '24 | Sale | 85.18 | 35,341 | 3,010,396 | 212,117 | Mar 07 06:54 PM | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Mar 05 '24 | Sale | 87.07 | 4,000 | 348,280 | 94,047 | Mar 07 05:32 PM | BIENAIME JEAN JACQUES | Director | Mar 05 '24 | Sale | 85.51 | 1,000 | 85,510 | 561,203 | Mar 07 05:35 PM | BIENAIME JEAN JACQUES | Director | Feb 27 '24 | Sale | 90.35 | 1,000 | 90,350 | 562,203 | Feb 29 05:05 PM | BIENAIME JEAN JACQUES | Director | Feb 09 '24 | Option Exercise | 63.10 | 15,000 | 946,500 | 434,602 | Feb 12 05:20 PM | BIENAIME JEAN JACQUES | Director | Feb 09 '24 | Sale | 88.28 | 15,000 | 1,324,200 | 419,602 | Feb 12 05:20 PM | BIENAIME JEAN JACQUES | Director | Feb 08 '24 | Option Exercise | 63.10 | 15,000 | 946,500 | 434,602 | Feb 12 05:20 PM | BIENAIME JEAN JACQUES | Director | Feb 08 '24 | Sale | 89.77 | 15,000 | 1,346,550 | 419,602 | Feb 12 05:20 PM | BIENAIME JEAN JACQUES | Director | Jan 10 '24 | Option Exercise | 63.10 | 10,000 | 631,000 | 435,162 | Jan 11 02:40 PM | BIENAIME JEAN JACQUES | Director | Jan 10 '24 | Sale | 96.38 | 10,000 | 963,800 | 425,162 | Jan 11 02:40 PM | BIENAIME JEAN JACQUES | Director | Jan 09 '24 | Option Exercise | 63.10 | 10,000 | 631,000 | 435,162 | Jan 11 02:40 PM | BIENAIME JEAN JACQUES | Director | Jan 09 '24 | Sale | 98.19 | 10,000 | 981,900 | 425,162 | Jan 11 02:40 PM | BIENAIME JEAN JACQUES | Director | Dec 21 '23 | Option Exercise | 63.10 | 10,000 | 631,000 | 435,112 | Dec 22 05:14 PM | BIENAIME JEAN JACQUES | Director | Dec 21 '23 | Sale | 93.99 | 10,000 | 939,900 | 425,112 | Dec 22 05:14 PM | Davis George Eric | EVP, Chief Legal Officer | Dec 13 '23 | Sale | 95.30 | 13,764 | 1,311,709 | 55,710 | Dec 14 06:18 PM | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Aug 16 '23 | Sale | 90.00 | 5,000 | 450,000 | 60,804 | Aug 17 03:57 PM | FUCHS HENRY J | President, Worldwide R&D | Aug 10 '23 | Sale | 90.43 | 12,000 | 1,085,111 | 176,187 | Aug 11 01:59 PM | Guyer Charles Greg | EVP, Chief Technical Officer | Aug 09 '23 | Sale | 93.30 | 5,360 | 500,109 | 40,041 | Aug 10 04:47 PM | Davis George Eric | EVP, Chief Legal Officer | Aug 08 '23 | Sale | 89.42 | 11,000 | 983,662 | 69,474 | Aug 09 07:08 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | Aug 08 '23 | Sale | 88.29 | 6,000 | 529,740 | 422,732 | Aug 09 07:05 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | Aug 07 '23 | Sale | 88.10 | 4,000 | 352,400 | 428,732 | Aug 09 07:05 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | May 12 '23 | Option Exercise | 67.81 | 46,500 | 3,153,165 | 472,713 | May 16 05:22 PM | MEIER RICHARD A | Director | May 12 '23 | Option Exercise | 67.81 | 8,500 | 576,385 | 117,494 | May 17 06:14 PM | HERON ELAINE J | Director | May 12 '23 | Option Exercise | 67.81 | 8,500 | 576,385 | 94,068 | May 17 06:14 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | May 11 '23 | Option Exercise | 67.81 | 30,000 | 2,034,300 | 456,213 | May 15 04:58 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | May 11 '23 | Sale | 94.67 | 30,000 | 2,840,226 | 426,213 | May 15 04:58 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | May 10 '23 | Option Exercise | 67.81 | 30,000 | 2,034,300 | 456,213 | May 11 05:04 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | May 10 '23 | Sale | 94.85 | 30,000 | 2,845,397 | 426,213 | May 11 05:04 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | May 09 '23 | Option Exercise | 67.81 | 30,000 | 2,034,300 | 456,213 | May 11 05:04 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | May 09 '23 | Sale | 94.93 | 30,000 | 2,847,973 | 426,213 | May 11 05:04 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 10 '23 | Option Exercise | 67.81 | 10,000 | 678,100 | 435,896 | Apr 12 04:08 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 10 '23 | Sale | 99.56 | 10,000 | 995,600 | 425,896 | Apr 12 04:08 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 06 '23 | Option Exercise | 67.81 | 10,000 | 678,100 | 435,896 | Apr 10 07:00 PM | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 06 '23 | Sale | 96.13 | 10,000 | 961,300 | 425,896 | Apr 10 07:00 PM | LAWLIS V BRYAN | Director | Apr 03 '23 | Option Exercise | 67.81 | 8,500 | 576,385 | 37,450 | Apr 04 07:59 PM | LAWLIS V BRYAN | Director | Apr 03 '23 | Sale | 97.09 | 8,500 | 825,265 | 28,950 | Apr 04 07:59 PM |
|